topiramate - Profile

What are the generic sources for topiramate and what is the scope of patent protection?

Topiramate is the generic ingredient in six branded drugs marketed by Upsher Smith Labs, Actavis Labs Fl, Ajanta Pharma Ltd, Alkem Labs Ltd, Amta, Ascent Pharms Inc, Dr Reddys, Glenmark Pharms Ltd, Lupin Ltd, Ph Health, Xiamen Lp Pharm Co, Zydus, Zydus Pharms, Supernus Pharms, Janssen Pharms, Aurobindo Pharma Ltd, Barr, Chartwell Rx, Rubicon Research, Senores Pharms, Strides Pharma, Teva, Twi Pharms, Watson Labs, Zydus Pharms Usa Inc, Azurity, Accord Hlthcare, Actavis Totowa, Aiping Pharm Inc, Aurobindo Pharma, Chartwell, Cipla Ltd, Hikma Pharms, Invagen Pharms, Natco, Pharmaco, Pliva Hrvatska Doo, Roxane, Sun Pharm, Sun Pharm Inds Ltd, Torrent Pharms, and Unichem Labs Ltd, and is included in fifty-five NDAs. There are twenty patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Topiramate has twenty-one patent family members in eleven countries.

There are three tentative approvals for this compound.

Summary for topiramate

International Patents:	21
US Patents:	20
Tradenames:	6
Applicants:	42
NDAs:	55
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for topiramate

Generic filers with tentative approvals for TOPIRAMATE

Applicant	Application No.	Strength	Dosage Form
		200MG	TABLET;ORAL
		100MG	TABLET;ORAL
		50MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for TOPIRAMATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPRONTIA	Oral Solution	topiramate	25 mg/mL	214679	1	2022-10-06
QUDEXY XR	Extended-release Capsules	topiramate	25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	205122	1	2015-12-24
TROKENDI XR	Extended-release Capsules	topiramate	25 mg, 50 mg, and 100 mg	201635	1	2014-05-12
TROKENDI XR	Extended-release Capsules	topiramate	200 mg	201635	1	2014-04-03
TOPAMAX	Tablets	topiramate	50 mg	020505	1	2005-09-08
TOPAMAX SPRINKLE	Capsules	topiramate	15 mg and 25 mg	020844	1	2005-09-07
TOPAMAX	Tablets	topiramate	25 mg, 100 mg and 200 mg	020505		2001-12-26

US Patents and Regulatory Information for topiramate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-001	Mar 11, 2014	AB2	RX	Yes	No
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-001	Mar 11, 2014	AB2	RX	Yes	No			Y
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-001	Mar 11, 2014	AB2	RX	Yes	No			Y
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-001	Mar 11, 2014	AB2	RX	Yes	No			Y

International Patents for topiramate

Country	Patent Number	Title	Estimated Expiration
South Korea	20160124930	서방성 토피라메이트 캡슐 (EXTENDED-RELEASE TOPIRAMATE CAPSULES)
South Korea	101674509
Australia	2007319141	Sustained-release formulations of topiramate
South Korea	20150132838	서방성 토피라메이트 캡슐 (EXTENDED-RELEASE TOPIRAMATE CAPSULES)

Supplementary Protection Certificates for topiramate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0138441	SPC/GB95/028	United Kingdom		PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
2317997	2190050-1	Sweden		PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212

Investment Scenario, Market Dynamics, and Financial Trajectory for Topiramate

Last updated: February 3, 2026

Executive Summary

Topiramate, a broad-spectrum anticonvulsant and migraine prophylactic, introduced in 1996, has evolved from a niche treatment to a multi-indication pharmaceutical asset. This analysis covers its current market position, future growth projections, and investment considerations by examining its therapeutic portfolio, competitive landscape, regulatory environment, and revenue potential.

---

Overview of Topiramate

• Generic Name: Topiramate

• Approved Since: 1996 (FDA)

• Therapeutic Areas:

  • Epilepsy (partial-onset seizures)
  • Migraine prophylaxis
  • Off-label uses: Weight management, bipolar disorder, alcohol dependence

• Existing Markets:

  • US: Dominant via generics (e.g., Teva, Mylan) and some brand sales (e.g., Topamax)
  • Europe: Similar patent and generic landscape
  • Emerging markets: Growing adoption

---

Market Dynamics

Market Size and Growth Projections

Indication	Estimated 2023 Market Value (USD Billion)	5-Year CAGR (%)	Comments
Epilepsy (global)	1.8	3–5	Significant base; driven by prevalence (~50 million globally)[1]
Migraine prophylaxis	1.2	4–6	Growing due to unmet needs and increased diagnosis
Off-label uses (e.g., weight loss)	Estimated $600 million (US)	10+ (off-label)	Demand driven by obesity and psychiatric applications

Note: Market estimates derived from IQVIA, GlobalData, and publicly available market research.

Key Market Drivers

• Increasing prevalence of epilepsy (~50 million globally) and migraines (~1 billion globally)[2].
• Generic penetration influences pricing and margins.
• Off-label use expansion in weight management and psychiatric disorders.
• Emerging markets providing growth opportunities due to rising healthcare infrastructure.

Competitive Landscape

Major Players	Market Share	Product Portfolio	Strengths
Teva, Mylan, Sandoz	70–80% (generics)	Multiple generic formulations	Price competitiveness, extensive distribution
Janssen (original)	N/A (patented phase till 2008)	Topamax, Brand Name	Brand recognition, patent protection (until 2008)
New Entrants	Limited	Biosimilars, novel formulations	Innovation in delivery, combination therapies

Patent and Regulatory Environment

• Patent expiration: US Patents for Topamax expired in 2008; generics dominate post-expiry.
• Regulatory pathways: EMA and FDA approve biosimilars, combination drugs, and novel formulations.
• Off-label prescribing: Significant in certain markets, impacting revenue models.

---

Financial Trajectory and Investment Outlook

Revenue Analysis

Revenue Source	2022 Estimate (USD Million)	Notes
Branded Topamax / Topiramate	$200–250	Declining due to patent expiry and generic competition
Generics	$1,200–1,500	Dominates revenue stream; volume-driven
Off-label/Other Uses	<$300	Limited by regulatory restrictions and market acceptance

Forecast for 2023–2027:

Scenario	2027USD Million	CAGR (%)	Assumptions
Base Case	$1,600–1,800	3–4	Steady generic competition, moderate off-label growth
Optimistic	$2,000–2,300	6–8	Increased off-label use, new formulations, or market expansion
Pessimistic	<$1,200	-2 to 0	Market saturation, regulatory restrictions, or pricing pressures

Profitability and Margins

• Gross Margin: Approx. 60–70% for original brands, <50% for generics.
• Operating Margin: 15–25%, declining with generic proliferation.
• Impact of Patent Expiry: Sharp decline (~70%) in revenue post-2008 patent expiration.

Investment Opportunities and Risks

Opportunities	Risks
Development of novel formulations	Price erosion due to generics
Expansion into emerging markets	Off-label use regulation and reimbursement issues
Strategic licensing or co-marketing	Competition from new therapies (e.g., CGRP inhibitors for migraines)
Repurposing for psychiatric disorders	Market saturation and patent cliff risks

Emerging Trends and Future Drivers

Trend	Implication
Biosimilar and generic adoption	Margin compression
Combination therapies	Potential for expanded indications
Digital health integration	Improved adherence, monitoring, and market penetration
Personalized medicine approaches	Targeted therapies enhancing topiramate’s profile

---

Comparison with Similar Drugs

Drug	Indication	Market Size (USD Billion)	Patent Status	Key Differentiators
Valproic Acid	Epilepsy, bipolar	2.1	Patent expired	Broader indication, safety concerns
Gabapentin	Neuropathic pain, epilepsy	1.5	Patent expired	High off-label use
Levetiracetam	Epilepsy	1.8	Patented until recently	Favorable side effect profile

Policy and Reimbursement Landscape

• Pricing pressures: Managed care organizations advocate for cost-effective alternatives.
• Reimbursement: Generics benefit from favorable policies, though off-label uses often lack insurance coverage.
• Regulatory restrictions: Off-label prescriptions face scrutiny; new indications require clinical validation.

---

Conclusion

The investment outlook for topiramate hinges on multiple factors:

• Market maturity: Significant decline in branded sales due to patent expiry, but sustained revenue from generics.
• Growth prospects: Limited in traditional indications; potential in off-label expansion and formulation innovation.
• Competitive environment: Dominated by generics, with added risks from biosimilars and alternative therapies.
• Financial trajectory: Moderate, with regional growth opportunities offsetting pricing pressures.

Investors should monitor regulatory developments, off-label market dynamics, and pipeline innovations to optimize their positioning in this mature but evolving market.

---

Key Takeaways

• Market maturity: Post-patent expiry, revenue primarily relies on generics with declining margins.
• Growth opportunities: Limited but present in emerging markets, off-label uses, and novel formulations.
• Competitive risk: Intense generic competition reduces profitability; biosimilar threats emerging.
• Innovation potential: Development of new delivery systems or combination therapies may revitalize interest.
• Regulatory landscape: Off-label prescribing and reimbursement policies significantly influence revenue streams.

---

FAQs

Q1: What is the current patent status of topiramate?
Topiramate's original patents expired in 2008 in the US and Europe, resulting in widespread generic availability.

Q2: Which markets offer the most growth potential for topiramate?
Emerging markets and off-label therapeutic areas present notable growth opportunities, especially with increasing healthcare infrastructure and demand for migraine and epileptic treatments.

Q3: How does generic competition impact topiramate’s revenue?
It significantly reduces profit margins and revenue share attributable to branded sales, shifting focus toward volume-driven generic markets.

Q4: What are the key risks facing topiramate as an investment?
Main risks include price erosion from generics, regulatory restrictions on off-label use, and competition from newer therapies such as CGRP inhibitors.

Q5: Are there ongoing developments or formulations that could influence topiramate’s market?
Yes, there is interest in extended-release formulations and combination therapies, which may improve adherence and open new indications.

---

References

[1] World Health Organization. Epilepsy factsheet. 2022.
[2] Goadsby PJ et al. Migraine. Nat Rev Dis Primers. 2017;3:17078.